# Terveystalo 2020 Results Strong improvement in profitability in Q4

CEO Ville Iho CFO Ilkka Laurila

### Agile response to fluctuations in demand was rewarded by strong financial performance in Q4


Revenue
EUR 279.7 Mill.
(+3.5%)

Adj. EBITA EUR 39.3 Mill. (+21.5%) **EPS**EUR **0.18**(+39.0%)


NPS 82.8 (+14.2%)

eNPS 18.0 (+100%) > 126,000 Covid-19 tests


# Strong sales in private and corporate customers as well as public occupational health & services




- Growth in insurance company sales, well-being services and vaccinations
- Appointments associated with various infections as well as demand for specialist appointments decreased considerably y-o-y
- Digital appointments more than quadrupled to ~242,000 visits
- Oct–Dec 2020 had 64 business days, + 2 days y-o-y



### 2020: Strong performance in a challenging year





11.2.2021

### We start the second corona year from a position of strength

6.9

Mill. customer visits 26%


Share of remote visits

1.2

Mill. Individual customers 309

Locations

2020 revenue by payer group, %



986 2020 Revenue, Mill. Euros

10% 2020 Adj. EBITA margin


13,000 professionals

TERVEYSTALO'S PLATFORM BUSINESS MODEL MATCHES CUSTOMERS WITH PRIVATE PRACTITIONERS AND INTEGRATES EPISODES INTO EFFECTIVE CARE CHAINS




### Already 26% of the appointments delivered remotely through our platform

#### Digital & remote services on care path



#### Physical services on care path

### Already 26% of the appointments delivered remotely through our platform



#### Physical services on care path

# From a single discipline approach to customer centric From local experts to network wide best practices From physical to hybrid

- The units focus expertise in selected areas and build multidisciplinary teams around the hybrid care path.
  - The first Focus specialist units will provide services related to mental well-being, musculoskeletal and abdominal diseases.



### **Outlook**



In the short term, the market environment is still uncertain because of the changes in consumer behavior resulting from the COVID-19 pandemic, and predicting demand is challenging in the short term. Demand for coronavirus testing is expected to remain high throughout the first half of 2021, and demand for healthcare services in general is expected to grow clearly year-on-year compared with the weak second-quarter reference period, providing that there will be no need to implement strict pandemic restriction measures as was the case in the first half of 2020.

Demand from corporate customers for preventive and statutory occupational health services is expected to remain stable. The recovery of demand for acute and non-urgent medical care is uncertain, owing to a reduction in general morbidity and the measures to restrict the pandemic. The proportion of remote services will increase considerably. Significant changes in the employment rate may be reflected in the underlying demand.

Overall demand from private customers is expected to remain normal, providing that, in particular, major restrictions to free movement can be avoided. However, there may be considerable differences between specialties in the short term because of variation in general morbidity and pandemic-related area-specific restrictive measures. Demand for remote services will increase considerably. Significant changes in consumer confidence may be reflected in the underlying demand.

Stable demand from the public sector is expected to continue in occupational health, service sales, and staffing services. Revenue from outsourcing business will fall, following the planned expiry of outsourcing contracts.


These views are based on the expected development of demand for Terveystalo's services within the next six months, compared with the past six months.

Ilkka Laurila, CFO


### Financial performance

### 2020 revenue






#### 2020 revenue by payer group, M€




### Strong trend in wellbeing and digital visits continues




<u>Terveystalo</u>

# Decent financial performance in a challenging year



### Revenue back on a growth track, profitability improved



# Investments in digital services increased IT costs, PPE procurement increases costs of materials

| M€                         | 10-12/2020 | 10-12/2019 | Change. % | 1-12/2020 | 1-12/2019 | Change. % |
|----------------------------|------------|------------|-----------|-----------|-----------|-----------|
| Revenue                    | 279.7      | 270.3      | 3.5       | 986.4     | 1 030.7   | -4.3      |
| Other operating income     | 0.8        | 0.8        | 2.0       | 2.7       | 2.1       | 29.0      |
| Purchase of materials      | -9.6       | -8.9       | 7.5       | -35.5     | -32.0     | 11.0      |
| Change in inventories      | -0.9       | -0.5       | 78.3      | 1.3       | -0.3      | >200.0    |
| External services          | -112.4     | -113.3     | -0.8      | -413.4    | -440.6    | -6.2      |
| Employee benefit expenses  | -84.6      | -81.3      | 3.3       | -310.2    | -314.3    | -1.3      |
| Rents. leases and premises | -3.8       | -4.0       | -4.6      | -16.3     | -16.0     | 2.0       |
| IT expenses                | -6.8       | -5.8       | 17.7      | -25.2     | -21.1     | 19.7      |
| Other operating expenses   | -8.6       | -9.8       | -12.7     | -31.5     | -37.3     | -15.5     |
| EBITDA                     | 53.7       | 46.8       | 14.8      | 158.3     | 171.2     | -7.5      |
| Adjustments*               | 0.8        | 1.0        |           | 4.5       | 5.1       |           |
| Adjusted EBITDA            | 54.5       | 47.8       | 14.1      | 162.8     | 176.3     | -7.7      |
| EBIT                       | 30.8       | 23.8       | 29.4      | 67.2      | 81.4      | -17.5     |

Variable costs

Semi-fixed costs. scalable on a unit level

Fixed costs. scalable on a group level

<sup>\*</sup>Adjustments are material items outside the ordinary course of business and these relate to acquisition related expenses. restructuring related expenses. gain /losses on sale of assets (net). strategic projects and other items affecting comparability.

### Liquidity at a good level


| m€                            | 31.12.2020 | 31.12.2019 |
|-------------------------------|------------|------------|
| ASSETS                        |            |            |
| Property. plant and equipment | 67.6       | 69.5       |
| Right of use assets           | 172.4      | 193.2      |
| Goodwill                      | 781.8      | 779.2      |
| Other intangible assets       | 152.2      | 161.9      |
| Other assets                  | 110.0      | 114.9      |
| Cash and cash equivalents     | 77.1       | 40.6       |
| TOTAL ASSETS                  | 1,361.0    | 1,359.3    |
|                               |            |            |
| EQUITY AND LIABILITIES        |            |            |
| TOTAL EQUITY                  | 571.4      | 541.2      |
| Interest bearing liabilities  | 389.5      | 390.8      |
| Other liabilities             | 178.5      | 198.0      |
| Lease liabilities             | 221.7      | 229.2      |
| TOTAL LIABILITIES             | 789.6      | 818.0      |
| TOTAL EQUITY AND LIABILITIES  | 1,361.0    | 1,359.3    |

- Cash and cash equivalents EUR 77.1 mill. (40.6).
- Total assets EUR 1,361.0 mill. (1,359.3).
- Equity attributable to owners of the parent company was EUR 571.4 (541.2) mill. The increase was due to an increase in retained earnings.
- Net debt EUR 490.9 mill. (548.2) Including IFRS 16 liabilities and EUR 325.9 mill. excluding IFRS 16 impact
- Net debt / adjusted EBITDA was 3.0 (3.1) and 2.8 excluding IFRS 16 impact

### Indebtedness below target




### Further positive development in DSO and DPO



### The share of intangible investments continue to grow (excluding M&A)

#### GROSS CAPEX. M€ AND %- OF REVENUE

#### **NET CAPEX. M€ AND %- OF REVENUE**



# We met all three sustainability criteria targets linked with financing agreement

NPS 82.8 (+14.2%) eNPS 18.0 (+100%) Mixed waste intensity 6.0 (+23.7 %)

Mixed waste intensity = Amount of mixed waste (metric tons) relative to total revenue (EUR 100 million) Target to decrease y-o-y, increase due to multiplied use of PPE

### Financial calendar and AGM in 2021



- Annual Report 2020 on week 7, 2021
- Interim report for January-March 2021 on Thursday, 29 April 2021
- Half-Year Report for January-June 2021 on Friday, 16 July 2021
- Interim report for January-September 2021 on Thursday, 28 October 2021

Annual General Meeting of Terveystalo Plc will be held on Thursday, 25 March 2021 in Helsinki.





### **Key Figures**

| Terveystalo Group, EUR million                                         | 10–12/<br>2020 | 10–12/<br>2019 | Change,<br>% | 2020  | 2019    | Change. % |
|------------------------------------------------------------------------|----------------|----------------|--------------|-------|---------|-----------|
| Revenue                                                                | 279.7          | 270.3          | 3.5          | 986.4 | 1,030.7 | -4.3      |
| Adjusted EBITDA * 1)                                                   | 54.5           | 47.8           | 14.1         | 162.8 | 176.3   | -7.7      |
| Adjusted EBITDA, % * 1)                                                | 19.5           | 17.7           | -            | 16.5  | 17.1    | -         |
| EBITDA 1)                                                              | 53.7           | 46.8           | 14.8         | 158.3 | 171.2   | -7.5      |
| EBITDA, % 1)                                                           | 19.2           | 17.3           | -            | 16.1  | 16.6    | -         |
| Adjusted earnings before interest. taxes and amortization (EBITA) * 1) | 39.3           | 32.3           | 21.5         | 101.9 | 115.1   | -11.5     |
| Adjusted EBITA, % *1)                                                  | 14.0           | 12.0           | -            | 10.3  | 11.2    | -         |
| EBITA 1)                                                               | 38.5           | 31.4           | 22.7         | 97.4  | 110.0   | -11.4     |
| EBITA, % <sup>1)</sup>                                                 | 13.8           | 11.6           | -            | 9.9   | 10.7    | -         |
| Adjusted EBIT * 1)                                                     | 31.6           | 24.8           | 27.5         | 71.6  | 86.5    | -17.2     |
| Adjusted EBIT, % * 1)                                                  | 11.3           | 9.2            | -            | 7.3   | 8.4     | -         |
| EBIT                                                                   | 30.8           | 23.8           | 29.4         | 67.2  | 81.4    | -17.5     |
| EBIT, %                                                                | 11.0           | 8.8            | _            | 6.8   | 7.9     | -         |
| Return on equity (ROE), $\%$ 1)                                        | -              | _              | _            | 8.2   | 10.3    | -         |
| Equity ratio, % <sup>1)</sup>                                          | -              | _              | _            | 42.1  | 39.9    | -         |
| Earnings per share (EUR)                                               | 0.18           | 0.13           | 39.0         | 0.36  | 0.43    | -15.5     |
| Gearing, % <sup>1)</sup>                                               | -              | _              | _            | 85.9  | 101.3   | -         |
| Net debt/adjusted EBITDA (last 12 months) 1)                           | -              | -              | -            | 3.0   | 3.1     | -         |

<sup>\*)</sup> Adjustments are material items outside the ordinary course of business, associated with acquisition-related expenses, restructuring-related expenses, gain on sale of assets, strategic projects, and other items affecting comparability.

1) Alternative performance measure. In addition to the IFRS figures, Terveystalo presents additional, alternative performance indicators which the company monitors internally and which provide the company management, investors, stock market analysts, and other stakeholders with important additional information concerning the company's financial performance, financial position, and cash flows. These performance indicators should not be reviewed separate from the IFRS figures and they should not be considered to replace the IFRS figures.

### **Key Figures**

| Terveystalo Group, EUR million                                             | 10-12/<br>2020 | 10-12/<br>2019 | Change, % | 2020  | 2019  | Change. % |
|----------------------------------------------------------------------------|----------------|----------------|-----------|-------|-------|-----------|
| Average personnel in person-years                                          | _              | _              | _         | 4,900 | 4,943 | -0.9      |
| Personnel (end of period)                                                  | _              | _              | _         | 8,253 | 8,685 | -5.0      |
| Private practitioners (end of period)                                      | _              | _              | _         | 5,057 | 5,068 | -0.2      |
| Adjusted EBITDA, excluding IFRS 16 *1)                                     | -              | -              | -         | 118.0 | 131.4 | -10.2     |
| Net debt, excluding IFRS 16                                                | =              | -              | -         | 325.9 | 366.4 | -11.1     |
| Adjusted net debt/ adjusted EBITDA, excluding IFRS 16 (last 12 months) *1) | -              | -              | -         | 2.8   | 2.8   | -         |
| Quality index <sup>2)</sup>                                                | _              | _              | _         | 94.2  | 96.4  | -2.3      |
| Net Promoter Score (NPS), appointments                                     | _              | _              | _         | 82.8  | 72.5  | 14.2      |
| Employee Net Promoter Score (eNPS) <sup>2)</sup>                           | _              | _              | _         | 18.0  | 9.0   | 100.0     |
| Mixed waste intensity <sup>2)</sup>                                        | _              | _              | _         | 6.0   | 4.98  | 23.7      |

<sup>\*)</sup> Adjustments are material items outside the ordinary course of business, associated with acquisition-related expenses, restructuring-related expenses, gain on sale of assets, strategic projects, and other items affecting comparability.

1) Alternative performance measure. In addition to the IFRS figures, Terveystalo presents additional, alternative performance indicators which the company monitors internally and which provide the company management, investors, stock market analysts, and other stakeholders with important additional information concerning the company's financial performance, financial position, and cash flows. These performance indicators should not be reviewed separate from the IFRS figures and they should not be considered to replace the IFRS figures.

<sup>2)</sup> The quality index consists of seven effectiveness indicators that describe the clinical and experienced quality, access to care, and the proportion of preventive care. eNPS is measured every six months; the reported figure is the result of the latest measurement.

Mixed waste intensity = Amount of mixed waste (metric tons) relative to total revenue (EUR 100 million)

### **Terveystalo**

Kohti parempaa.









